A phase 1b study of AFM13 CD30/CD16A bispecific antibody in combination with pembrolizumab in r/r HL demonstrated an ORR of 88%[103], and there is an ongoing study evaluating the safety and efficacy of mosunetuzumab (CD20/CD3) in combination with atezolizumab in r/r NHL and CLL (NCT02500407). The gene discussed is MS4A1; the disease is non-Hodgkin lymphoma.